Wall Street Journal (01/10/12) Dooren, Jennifer Corbett
Pradaxa, the first drug to gain approval as part of a new generation of blood thinners to lower stroke risk, was associated with an increased risk of heart attack in a new study published online in the Archives of Internal Medicine. The finding may slow the adoption of newer blood-thinning medications and prompt some doctors to leave more patients on warfarin, a decades-old drug for the condition. But some doctors cautioned that the study turned up only a small increase in the actual number of heart attacks and noted that Pradaxa has been effective at reducing stroke. Pradaxa is marketed by Boehringer Ingelheim.

Read the complete article